Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Change in Cash (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Change in Cash for 16 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 295.03% to -$4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 202.41% year-over-year, with the annual reading at $8.7 million for FY2025, 202.41% up from the prior year.
  • Change in Cash for Q4 2025 was -$4.5 million at Plus Therapeutics, down from $11.1 million in the prior quarter.
  • The five-year high for Change in Cash was $11.1 million in Q3 2025, with the low at -$7.6 million in Q2 2025.
  • Average Change in Cash over 5 years is -$208294.1, with a median of -$1.8 million recorded in 2023.
  • The sharpest move saw Change in Cash surged 498.5% in 2021, then tumbled 3423.42% in 2024.
  • Over 5 years, Change in Cash stood at $6.1 million in 2021, then plummeted by 135.17% to -$2.1 million in 2022, then decreased by 14.26% to -$2.5 million in 2023, then soared by 53.22% to -$1.1 million in 2024, then crashed by 295.03% to -$4.5 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$4.5 million, $11.1 million, and -$7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.